Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New shot aims to stop the maddening itch of prurigo nodularis

NCT ID NCT06554509

First seen May 06, 2026 · Last updated May 21, 2026 · Updated 2 times

Summary

This study tests an experimental drug called SHR-1819, given as an injection, to see if it can safely reduce the intense itching caused by prurigo nodularis—a skin condition with hard, itchy bumps. About 423 adults will receive either the drug or a placebo, and researchers will track how much their itch scores drop over 16 to 24 weeks. The goal is to find a new option for people whose itching hasn't been controlled by other treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRURIGO NODULARIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100032, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.